In gliomas, when the IDH1 mutation is present, it is typically found throughout the entirety of otherwise heterogeneous tumors, which makes targeting vulnerabilities conferred by mutant IDH1 very appealing [5]. This evidence concerns the gene IDH1 and glioma.